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1. Introduction 
Although the mortality due to melanoma or malignant mutated pigment cell cancer has 
begun to stabilize in developed country (1, 2), the disease shows, however a substantial 
increased incidence which, in term of public health, represents a high burden (3-5). As well 
known, among the risk factors leading to melanoma there is exposition to solar ultraviolet 
radiation associated to sensitive genetic background (6-9). Numerous reports have shown 
that important key genes such as MC1R or melanocortin-1 receptor, BRAF, NRAS as well as 
IDH1 were mutated in melanoma (10-16). Once metastases occur, the rate of patients’5 year 
survival is low (17), at this stage, it was shown that melanoma develops a resistance to 
current chemotherapy associated to high level of apoptosis inhibition (18, 19). Treatment is 
becoming difficult, useless and even futile. Although new generation of drugs is in 
development aiming to target mutated gene expression product sustaining tumor cell 
proliferation, i.e., BRAF (20) there is an urgent need for novel therapeutic approaches such 
as cancer immunotherapy involving immune effectors specifically activated for killing 
tumor cells. 
2. Stimulating antimelanoma immune effectors 
Efforts toward development of cancer immunotherapy have mainly focused on the 
possibility to vaccinate patients for obtaining specific immune response against their own 
cancer. The characterization of numerous tumor associated antigens or TAAs, especially in 
the context of melanoma with melanoma associated antigens (MAAs) such as gp100, 
MAGE-1, MAGE-3, MART-1 as well as tyrosinase has allowed to derive epitopes used for 
inducing CTLs (cytotoxic T lymphocytes) (21-28). In most of the case, the tumor associated 
antigens which belong to the group of differentiation antigens shared with normal tissue, 
are less immunogenic than those derived from pathogen (virus, bacteria). Thus several 
procedures were used in order to increase the MAA's immunogenicity such as amino-acid 
sequence alteration, cytokine boosting. As well known, the immunogenic peptide, in 
general, harboring anchor residues that bind to the MHC (major histocompatibility 
complex) antigen presenting molecule forming a stable complex that is essential for immune 
cognate recognition (29). As an example, the human MHC class I, HLA-A2 bind with  
high affinity peptides with either leucine/methionine at position 2 or valine at position 9 in 
the 9-10 amino-acid sequence. Thus a substitution of anchor residues at the indicated 
position (2 and/or 9) by high affinity binding ones will render the modified peptide, i.e.,  
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gp100 209-217 2M (IMDQVFSV) more immunogenic than the native sequence, i.e.,  
gp100 209-217 (ITDQVFSV) (30). In clinical trials, vaccination of patients with the modified 
peptide, gp100 209-217 2M has been shown to increase the number of CTL precursors 
recognizing not only the modified peptide, but also the native one (31). It is worth to note 
that, although alteration in amino-acid sequence has led to increasing the immunogenicity 
of the tumor associated antigenic peptide, other factors were necessary to achieve objective 
clinical response, i.e., the use of adjuvant and cytokine. Thus, the oil-based montanide ISA 
51 or IFA (incomplete Freund’s adjuvant) (32,33) being shown to stimulate immune 
response was frequently used (34,35) contributing to the overall T cell immune stimulation. 
However, as reported by Rosenberg and colleagues, the immune response leading to 
objective clinical response was observed only when patients received also IL-2 along with 
the vaccine (31). Likewise, Weber and colleagues (36), Lee and colleagues (37), have shown 
the implication of GMCSF (granulocyte-macrophage-colony stimulating factor) and IL-12, 
respectively as boosting factors that stimulated CTL response to melanoma peptides gp100, 
tyrosinase and MART-1. 
3. Immune and clinical response to melanoma vaccination 
Results from numerous vaccine trials using melanoma peptides in patients with either 
primary or metastatic resected tumors showed the presence of CTLs as measured by the 
release of IFN-gamma (ELISA, Elispot tests), Cr 51 cytotoxicity assay, TCR specificity 
assay with tetramer analysis, skin test, among other assays. However, as far as could be 
observed, the generated CTLs from immunization approaches were variable in their 
antimelanoma potency which could be ranged, in the case of gp100 vaccine, from 
cytotoxic only to modified peptide pulsed target, to cytotoxic to both native and modified 
peptide sensitized target but not melanoma, or recognizing HLA matched melanoma 
peptide pulsed target and finally recognizing melanomas HLA-A2+ gp100+ (38). 
Furthermore, the immune response did not always correlate with tumor regression, 
although there were indications that positive immune response obtained in ELISA and 
Elispot assays correlated better with prolonged relapse-free survival (35). Overall, the lack 
of correlation between the high proportion of positive immune response among 
immunized melanoma patients and objective clinical effects could be explained by the 
difficulty in obtaining CD8+CTLs with specific high avidities. Another possibility is that 
tumor cells might express low number of specific epitopes on their cell surface, or simply 
down regulated the MHC I presenting antigenic peptide. Another approach developed by 
the group led by Rosenberg consisting to isolate reactive immune effectors infiltrating the 
tumor (TILs or tumor infiltrating lymphocytes) which have shown to produce objective 
cancer regression in treated patients (39-42). The prior lymphodepletion by treatment with 
cyclophosphamide and fludarabine has probably enabled the persistence and the function 
of adoptive transferred cells. The onset of autoimmune melanocyte destruction that 
accompanied cancer regression is considered as the hallmark of efficient reactive effector 
cells that have targeted also normal tissue expressing melanocyte differentiation antigen. 
The efficacy of T cell transfer as reported by the Rosenberg’s group in comparison with 
the active immunization of patients with melanoma could be explained by the fact that 
reactive T cells were already selected in the work of the former and the lymphodepletion 
has, in addition, contributed to disrupt and overcome some tolerogenic and normal 
homeostatic regulation. 
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4. Targeting IGF-1 based melanoma immunotherapy 
4.1 IGF-1 as target in melanoma immunotherapy 
Beside the above strategies that are essentially based on activation of immune effectors 
through antigenic differentiation peptides, other strategy has been explored by means of 
gene transfection aiming to increase tumor immunogenicity in disrupting its immune 
tolerance/suppression. There were for example experimental models in which gene coding 
for either immunogenic foreign protein such as OVA (egg albumin) or MHC-I were 
introduced into tumor cells making them sensitive to immune effectors (CTLs)(43-48). In the 
following chapter we reported results concerning the strategy that consisted to inhibit 
melanoma autocrine growth factor IGF-1 expression and its consequences upon the 
recruitment of antimelanoma immune effectors. The strategy is thus based on the use of 
antisense episomal vector as well as specific antibody targeting melanoma IGF-1 expression. 
Concerning the experimental model, the B16 melanoma cell line originated from the mouse 
strain C57Bl/6 (H-2b) was used (49). There are several variants derived from the B16 cell 
line. The most studied melanoma variants are the highly metastatic B16-F10, BL6 and the 
subline B78H1 (50-52). The latter one is mainly devoid of TAP2 gene as well as MHC-I K b 
and D b which are weakly expressed in the formers and whose expression is inducible by 
IFN-γ (interferon gamma). 
Although widely used the B16 melanoma was subject to critics according to which it was 
not a good experimental model due to differences with the human counterparts, particularly 
the lack of some key mutations such as those found in PTEN and BRAF (53,54). In general, 
cancer cells are heterogeneous with constant developmental evolution and adaptation, 
leading to regular acquisition of several new emerging mutant phenotypes (55,56), it is 
therefore difficult to find out a best defined one model for studying all complex aspects 
relevant to the cancer biology. Nevertheless, approaches through a well known model 
would allow to analyze and dissect the mechanisms underlying the deregulated growth of 
the relevant malignant cancer type. In the present work we focused on IGF-1 expressed in 
melanoma which is known as the most prominent growth factor produced by the majority 
of cancer types. Thus, as a pleotrophic growth factor, IGF-1 plays an essential role in cellular 
proliferation and apoptosis inhibition (57,58). Therefore, targeting IGF-1 appeared as an 
effective strategy for the control of tumor development and tumor invasiveness. This 
strategy had been already applied to experimental models of glioma and hepatocarcinoma, 
leading to prevent the tumorigenicity of the former and rendering the latter less tumorigenic 
(59,60). In these reported studies the control exerted on tumor development as well as on 
tumor rejection was undoubtedly due to the action of immune effectors, since it was 
reported the presence of CD8+ T cells at the site of tumor rejection. 
4.2 In vitro analyses of inhibited IGF-1 melanoma cells 
As stated above, the two procedures used for inhibiting IGF-1 expression in B16 
melanoma cells were transfection of tumor cells with antisense episomal vector as well as 
treatment with specific antibodies. The IGF-1 episomal vector harboring IGF-1 antisense 
cDNA was constructed as depicted in the work reported by the group led by J.Ilan from 
Case Western Reserve University, Cleveland, Ohio (USA) (61). Briefly, the expression 
vector construct, a gift from Dr Ilan, incorporated EBV (Epstein-Bar virus) replicative 
signals, an IGF-1 cDNA transcriptional cassette, a gene encoding nuclear antigen 1 and a 
metallothionein-I promoter. This construct is episomal and drive extrachrosomal 
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replication. The vector was transfected to B16 melanoma cells by electroporation giving 
rise to subclones selected according to their resistance to the selective pressure of 
hygromycin B. It was shown that activation of the transgene leading to extinguish IGF-1 
expression did not affect the viability of transfected melanoma cells (62). Concerning the 
treatment using specific antibodies, the B16 melanoma cells were submitted to anti-IGF-1 
antibodies that were made, in the present work, from goat and available commercially 
(Abcys, France). Two treatment cycles in the presence of heterologous complement 
(rabbit) were performed and the cells that have survived were subcloned. The two IGF-1 
inhibitory procedures have led to obtention of subclones showing abrogated IGF-1 
expression as ascertained by immunocytochemical assays (62). Thereafter, the inhibited 
IGF- 1 melanoma cells were submitted to analyses concerning mainly their morphology as 
well as the expression of their cell surface molecules in comparison to parental cells. It 
was shown that the inhibited IGF-1 B16 did not reveal noticeable difference with parental 
cells relevant to their morphology, their in vitro growth in culture as well as their 
adherence properties. It is worth to note that results reported from studies of C6 glioma 
have indicated a slight difference in the morphology between wild-type and transfected 
cells, at least in the early period of cell culture (61). Concerning the expression of cell 
surface molecules, studies were focused on those involved in immune activation, mainly 
the MHC-I and B7.1, as well as in cellular interactions such as the family members of 
integrin and tetraspanin molecules. From the results obtained, it was shown that the 
expression of molecules known for their implication in the immune activation processes 
remained unmodified (62). The results obtained were thus different from previously 
observed when glioblastoma C6 and hepatoma LF were transfected with antisense IGF-1 
vector. Indeed, in these studies, the IGF-1 modified cells exhibited either an upregulation 
of MHC-I and B7.1 expression (glioma C6 cells) (63) or a strong increase of MHC-I 
expression (hepatoma LF cells) (62). 
Among the group of molecules involved in cellular interaction, an alteration in the 
expression of the tetraspanin CD9 but not CD81 was essentially observed. The expression of 
the integrin α4/CD49d remained unchanged. The fact that only one member of the 
tetraspanin family molecules was affected is of interest and suggested that the tetraspanin 
CD9 and CD81 followed different pathways in their expression. It is worth to note the 
implication of CD9 but not CD81 in the cancer process as reported elsewhere (64). 
4.3 In vivo tumor development of inhibited IGF-1 melanoma cells 
The potential of inhibited IGF-1 B16 modified melanoma cells to develop into solid 
tumors in vivo were assessed (62). 25X1000 cells from either inhibited IGF-1 or parental 
cells were thus subscutaneously injected to C57BL/6 mice, their syngeneic host. The 
development of injected cell suspensions into solid tumors was followed up by regular 
examination and measures using a caliper. It was shown that solid tumors were 
developed in syngeneic hosts with a delay when modified B16 cells inhibited in their IGF-
1 expression were injected as compared to the parental counterparts. The difference was 
significant and resulted in tumors with a mean size smaller than that of parental cells in 
the interval of time starting from the cell injection to the first apparition of lethal tumors 
which were observed in all recipients of injected parental cells. On the other hand, a 
proportion of 40-50% of recipients injected with modified B16 cells (IGF-1 inhibited) 
survived free of tumor for more than three months while no survival was observed 
among the recipients of parental cells. 
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4.4 Characterization of immune effectors stimulated by modified melanoma cells 
exhibiting inhibited IGF-1 expression 
The fact that modified (IGF-1 inhibited) B16 cells developed solid tumors in syngeneic hosts 
with an aggressiveness lesser than parental cells suggested the presence of effector elements 
in host organisms controlling the outgrowth of modified cells (62). Since there was no 
difference between parental and inhibited IGF-1 B16 modified cells related to their in vitro 
cell culture expansion and their in vivo growth in immunocompromised recipients (NOD- 
SCID mice) (Nguyen et.al., unpublished results), it was assumed that tumor development 
from modified B16 cells in syngeneic host was regulated by adaptive immune effectors. In 
order to characterize the immune effectors controlling in vivo tumor development, 
experiments were performed using melanoma cells, either from inhibited IGF-1 or parental 
type, for vaccinating syngeneic immunocompetent hosts (65). The two types of melanoma 
cells were first blocked by mytomycin C treatment or by several frozen and thawed cycles. 
The blocked cells were subsequently injected to C57Bl/6 mice in vaccination purpose. The 
spleen cells and the sera from vaccinated animals harvested 10-15 days after were assessed 
for their effects upon B16 tumor cells in comparison to that of control untreated animals . 
The results obtained with the serum collected from mice vaccinated with parental cells 
showed no difference with the control serum from untreated animals. On the contrary, the 
serum collected from mice vaccinated with modified (IGF-1 inhibited) cells revealed the 
presence of antibodies that recognized not only modified, IGF-1 inhibited B16 cells but also 
their parental counterparts. This aspect was essentially observed in cytometry (FACS) 
analyses as well as in cytotoxic assays. Thus, in cytometry analyses the mean fluorescence 
obtained with serum from mice vaccinated with modified cells was 7-9 fold higher as 
compared to that obtained with serum from mice injected with parental B16 cells which was 
not different to the results from normal serum. Moreover, only serum collected from mice 
vaccinated with modified B16 cells exhibited cytotoxic activities against melanoma cells in 
the presence of heterologous (rabbit) complement, while practically no cytotoxic effects 
were observed with serum from mice injected with parental cells. Concerning the cellular 
effectors, in vitro cytotoxic assays showed that spleen cells harvested from mice injected 
with modified, IGF-1 inhibited B16 cells were able to kill melanoma cells, either of parental 
or modified type. On the contrary, melanoma cells were not affected by the presence of 
spleen cells from mice injected with parental cells as well as with spleen cells from normal 
untreated mice (65). 
These immune, humoral and cellular effector elements were also analyzed for their effects 
on the in vivo tumor development. In these in vivo assays, serum or spleen cells from 
mice vaccinated either with parental or modified, inhibited IGF-1 cells were injected 
together with melanoma cells to syngeneic hosts. Results obtained have shown that only 
spleen cells but not the immune serum from mice vaccinated with modified, IGF-1 
inhibited B16 cells were able to control the tumor development in syngeneic hosts. No 
effect on tumor growth was observed with the spleen cells from mice vaccinated with 
parental cells or spleen cells from control untreated mice as well as their serum (65, 66). 
The discrepancy between the in vitro and in vivo, humoral and cellular results concerning 
the case of mice vaccinated with modified-inhibited IGF-1 cells could be explained by the 
cell surface movement or capping phenomenon which could mask the antibody to 
ADCC/complement fixing lysis. Another alternative could be relevant to the short half-
life of antibody molecules compared to cellular effectors that would persist longer in the 
syngeneic host organisms. 
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Experiments were further performed for characterizing the active anti-tumor cell 
population(s) from spleen cells of mice vaccinated with modified, IGF-1 inhibited B16 cells. 
The above immune spleen cell suspension was thus submitted to negative selection by 
means of protein A - sepharose beads coated with specific antibody to CD4, CD8, NK 
(NK1.1), CD25, Ig (Immunoglobulin) and B220. It was shown that the anti-tumor activity 
was affected when spleen cell population was incubated with anti-CD8 antibody coated 
beads and removed from the cell suspension. The treatment of spleen cell suspension with 
other antibody-coated beads did not affect its anti-melanoma activity, indicating that spleen 
CD8+ T cells were the main immune effectors controlling in vivo melanoma development 
(66). 
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